Review finds no support for proactive monitoring of biologics in IBD
Routine monitoring no better than conventional management with anti-TNF therapy, researchers show
Proactive therapeutic drug monitoring of anti-TNF therapy offers no clinical benefit in patients with inflammatory bowel disease, regardless of disease activity, a meta-analysis shows.
Although routine monitoring of serum biologic levels has been proposed to improve outcomes in this clinical setting, US-led researchers say it is no better than conventional management.
However, they add that therapeutic drug monitoring (TDM) in paediatric patients “merits further consideration” as standard anti-TNF dosing regimens may
